Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 210-215

  Meyer, A H ^a   Stroux, A ^a   Lerch, K ^a   Eucker, J ^a   Eitle, J ^b   Hohloch, K ^b   Andrzejak, M ^a   Possinger, K ^a   Dorken B ^a   Pezzutto, A ^a   Scholz, C W ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c VIVANTES KLINIKUM AM URBAN   (Germany)

Author keywords

Additional malignancies; Marginal zone lymphoma; Risk factors; Transformation

Indexed keywords

LACTATE DEHYDROGENASE;

ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL EVALUATION; CRITICAL ILLNESS RATING SCALE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MARGINAL ZONE LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADDITIONAL MALIGNANCIES; MARGINAL ZONE LYMPHOMA; RISK FACTORS; TRANSFORMATION;

ADULT; AGED; AGED, 80 AND OVER; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905396838     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt507     Document Type: Article

References (23)

1. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon: International Agency for Research on Cancer, 2008.
2. Berger F, Felman P, Thieblemont C et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950-1956.
3. Zinzani PL, Magagnoli M, Galieni P et al. Nongastrointestinal low-grade mucosaassociated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999; 17: 1254.
4. Thieblemont C, Coiffier B. Management of marginal zone lymphomas. Curr Treat Options Oncol 2006; 7: 213-222.
5. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 171-178.
6. Altman DG, De Stavola BL, Love SB et al. Review of survival analyses published in cancer journals. Br J Cancer 1995; 72: 511-518.
7. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
8. Thieblemont C, Berger F, Dumontet C et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95: 802-806.
9. Zucca E, Conconi A, Pedrinis E et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489-2495.
10. Mazloom A, Medeiros LJ, McLaughlin PW et al. Marginal zone lymphomas: factors that affect the final outcome. Cancer 2010; 116: 4291-4298.
11. Conconi A, Motta M, Bertoni F et al. Patterns of survival of follicular lymphomas at a single institution through three decades. Leuk Lymphoma 2010; 51: 1028-1034.
12. Zucca E, Conconi A, Laszlo D et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginalzone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013; 31: 565-572.
13. Thieblemont C, Bastion Y, Berger F et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997; 15: 1624-1630.
14. Traverse-Glehen A, Bertoni F, Thieblemont C et al. Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma. Oncology (Williston Park) 2012; 26: 92-99, 103-104.
15. Thieblemont C, Davi F, Noguera ME et al. Splenic marginal zone lymphoma: current knowledge and future directions. Oncology (Williston Park) 2012; 26: 194-202.
16. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program 2005; 1: 307-313.
17. Angelopoulou MK, Kalpadakis C, Pangalis GA et al. Nodal marginal zone lymphoma. Leuk Lymphoma 2013 September 5 [epub ahead of print], doi:10.3109/10428194.2013.840888.
18. Al-Tourah AJ, Gill KK, Chhanabhai M et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 5165-5169.
19. Bernstein SH, Burack WR. The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 2009; 1: 532-541.
20. Tsang RW, Gospodarowicz MK, Pintilie M et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21: 4157-4164.
21. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471-1475.
22. Lenz G, Dreyling M, Schiegnitz E et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926-4933.
23. Zucca E, Pinotti G, Roggero E et al. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma. Ann Oncol 1995; 6: 726-728.